Structure-Based Drug Design - Will crystallisation 'chaperones' make all proteins crystallisable? By Dr Chun-wa Chung Macromolecular x-ray crystallography is usually an integral part of small molecule drug discovery for soluble targets. Recent advances in the crystallography of membrane proteins, such as ion channels and G-protein-coupled receptors, have opened up the… Read More
By Dr Susanta K. Sarkar The current challenges facing drug discovery and development in terms of attrition are well documented. This article discusses how molecular imaging approaches from bench to bedside can not only streamline drug development, but also open up new opportunities in the treatment management of targeted therapies. Read More
Share Share Tweet Email A perspective on scientific innovation in the pharmaceutical industry A perspective on scientific innovation in the pharmaceutical industry By Dr Joseph B. Bolen With a tarnished reputation and a lack of sustainable innovation this article argues that, maybe, it is time for the pharmaceutical industry to… Read More
Bringing Cost and Process Efficiency to Next Generation Sequencing By Dr Fred P. Ernani, and Dr Emily M. LeProust While next-generation sequencing has revolutionised the way genomes are sequenced, this technology possesses a fundamental weakness - the inability to easily target specific regions of a genome. To address this, a… Read More
Automation Of Solid/Powder Dispensing: Much needed, but cautiously used! By Dr John Comley This article investigates solid/powder dispensing in pharma and biotech, examines where it is most used, whether there exists a need to apply automation and what is motivating its wider use today. It reveals how concerns over problematic… Read More
Overcoming the Limitations of Chemical Structure By Dr Andy Vinter, Dr Steve Gardner and Dr Sally Rose The pharmaceutical business has been profoundly hampered by a ubiquitous and unexpected obstacles; the way it draws its chemical compounds. Scientists, patent agents and business decision makers from R&D, safety, and in-licensing are… Read More
Modular Automation for Screening: A cost/benefit analysis By Dr Jonathan Wingfield Cost is now a key driver for pharmaceutical companies and in many respects shapes the capital, revenue and resource decisions that have to be made during the drug discovery process. Where companies are resource rich, the need for fully… Read More
LIMS vs ELNs - Arch enemies or best of friends? By David Morris Since the first appearance of laboratory information management systems (LIMS) in the late 1960s, this technology has become commonplace in many, if not most, research and commercial laboratories. This considerable development in LIMS is in response to… Read More
The Benefits of Biological Modelling By Gordon Webster The enormous challenge posed by the complexity of biological systems represents a potential intellectual impasse to researchers and threatens to stall future progress in basic biology and healthcare. In recent years, increasing reliance on correlative approaches to biology has failed to resolve… Read More
Generation II DNA Sequencing Technologies By Dr Stephen F. Kingsmore, Dr Jenny C. van Velkinburgh, Dr Joann Mudge, and Dr Gregory D. May Generation II DNA sequencing has been widely heralded as a disruptive technology, generating tens of millions of random short sequences at efficiencies up to 20,000-fold greater than… Read More
Letting the Target Determine your Compound Acquisition Strategy By Dr John Harris With compound libraries likely to remain the cornerstone of hit and lead discovery for the foreseeable future, this paper seeks to summarise current and future approaches to optimal library design and compound acquisition, using examples and experimental evidence… Read More
The Microplate Market Past, Present and Future By Dr Peter Banks Microplates and the peripheral markets of liquid handling and detection technologies exist within almost all laboratories performing assays. This article discusses what, if any, are their growth expectations and whether there are new technologies on the horizon that could… Read More
Building a Robust Portfolio of New Medicines to Combat Malaria By Dr Timothy N.C. Wells Malaria is one of the biggest killers of our time. Current estimates from the World Health Organisation (WHO) suggest that more than 250 million people are at risk worldwide. More significantly, almost a million people… Read More
Natural Product Pharmaceuticals - The third generation By Dr Melanie McCullagh Compounds derived from natural products have made a big impact on the pharmaceutical industry. Of the 1,010 NCEs approved between January 1981 and June 2006, 43 were unaltered natural products (NPs) and a further 232 (23%) were second generation… Read More
Biomarker Signal Definition By Dr Gordon F. Kapke and Dr Nigel Brown Due to the numerous challenges in the industry, pharmaceutical companies are examining all aspects of the drug development process and rebuilding their associated business models as necessary. Companies need to improve success in late stage development, but what… Read More
qPCR Assays - End user practices and latest vendor offerings By Dr John Comley This review provides an insight into real-time quantitative PCR (qPCR) assays today. Using end-user feedback it investigates interest in the targets for qPCR applications; primary application areas for qPCR analyses; the importance of emerging applications; how… Read More